类器官和器官芯片技术在妇产科领域的应用研究取得了显著进展。类器官通过三维培养技术模拟人体器官的结构和功能,为研究子宫内膜异位症、卵巢癌等妇科疾病提供了新的实验模型,揭示了疾病的分子机制,并为药物筛选和个性化治疗提供了重...类器官和器官芯片技术在妇产科领域的应用研究取得了显著进展。类器官通过三维培养技术模拟人体器官的结构和功能,为研究子宫内膜异位症、卵巢癌等妇科疾病提供了新的实验模型,揭示了疾病的分子机制,并为药物筛选和个性化治疗提供了重要工具。子宫内膜类器官能够再现月经周期和胚胎着床过程,为不孕症和早期妊娠失败的研究提供了新的视角;卵巢类器官则在卵巢功能障碍和卵巢癌的研究中发挥了重要作用。器官芯片技术通过微流控系统模拟子宫和胎盘的微环境,提供了更为精确的实验平台。子宫芯片在月经周期调控、胚胎着床和子宫疾病研究中展现了巨大的应用潜力;胎盘芯片则为妊娠相关疾病的研究和药物筛选提供了新的方法。尽管面临技术标准化、伦理和高成本等挑战,类器官和器官芯片技术在妇产科领域的应用前景广阔,未来有望在临床诊断、药物研发和个性化医疗中发挥更大的作用。Significant progress has been made in the application of organoid and organ microarray technology in the field of obstetrics and gynecology. Organoids simulate the structure and function of human organs through three-dimensional culture technology, providing a new experimental model for the study of endometriosis, ovarian cancer and other gynecological diseases, revealing the molecular mechanism of the disease, and providing an important tool for drug screening and personalized treatment. Endometrial organoids can reproduce the menstrual cycle and embryo implantation process, providing a new perspective for the study of infertility and early pregnancy failure;ovarian organoids play an important role in the study of ovarian dysfunction and ovarian cancer. Organ chip technology provides a more accurate experimental platform by simulating the microenvironment of the uterus and placenta through a microfluidic system. Uterine microarrays have shown great potential in the study of menstrual cycle regulation, embryo implantation and uterine diseases;placental microarrays provide new methods for the study of pregnancy-related diseases and drug screening. Despite the challenges of technical standardization, ethics and high cost, organoids and organ chip technology have broad application prospects in the field of obstetrics and gynecology and are expected to play a greater role in clinical diagnosis, drug research and development and personalized medicine in the future.展开更多
液体活检技术在妇科恶性肿瘤中的应用研究取得了显著进展,为临床诊断和治疗带来了新的希望。作为一种无创性检测方法,液体活检通过分析血液中的循环肿瘤细胞(CTCs)、循环肿瘤DNA (ctDNA)及外泌体等生物标志物,实现了对肿瘤的早期诊断、...液体活检技术在妇科恶性肿瘤中的应用研究取得了显著进展,为临床诊断和治疗带来了新的希望。作为一种无创性检测方法,液体活检通过分析血液中的循环肿瘤细胞(CTCs)、循环肿瘤DNA (ctDNA)及外泌体等生物标志物,实现了对肿瘤的早期诊断、治疗监测和预后评估。其非侵入性和动态监测能力使其在克服传统组织活检局限性方面展现出独特优势。液体活检不仅能够为妇科恶性肿瘤的早期诊断做出贡献,还能在治疗过程中实时追踪肿瘤变化,指导个体化治疗策略的制定。然而,液体活检技术在临床应用中仍面临灵敏度、特异性、标准化等挑战。未来,随着技术的不断完善和研究的深入,液体活检有望在妇科恶性肿瘤的管理中发挥更为重要的作用,为患者提供更为精准和个性化的医疗服务。The application of liquid biopsy technique in gynecological malignant tumor has made remarkable progress, which brings new hope for clinical diagnosis and treatment. As a noninvasive test, liquid biopsy achieves early diagnosis, treatment monitoring, and prognostic evaluation of tumors by analyzing biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes in the blood. Its non-invasive and dynamic monitoring capabilities give it unique advantages in overcoming the limitations of traditional tissue biopsy. Liquid biopsy can not only contribute to the early diagnosis of gynecological malignancies, but also track tumor changes in real time during treatment and guide the development of individualized treatment strategies. However, liquid biopsy techniques still face challenges such as sensitivity, specificity, and standardization in clinical applications. In the future, with the continuous improvement of technology and the deepening of research, liquid biopsy is expected to play a more important role in the management of gynecological malignancies and provide more accurate and personalized medical services for patients.展开更多
文摘类器官和器官芯片技术在妇产科领域的应用研究取得了显著进展。类器官通过三维培养技术模拟人体器官的结构和功能,为研究子宫内膜异位症、卵巢癌等妇科疾病提供了新的实验模型,揭示了疾病的分子机制,并为药物筛选和个性化治疗提供了重要工具。子宫内膜类器官能够再现月经周期和胚胎着床过程,为不孕症和早期妊娠失败的研究提供了新的视角;卵巢类器官则在卵巢功能障碍和卵巢癌的研究中发挥了重要作用。器官芯片技术通过微流控系统模拟子宫和胎盘的微环境,提供了更为精确的实验平台。子宫芯片在月经周期调控、胚胎着床和子宫疾病研究中展现了巨大的应用潜力;胎盘芯片则为妊娠相关疾病的研究和药物筛选提供了新的方法。尽管面临技术标准化、伦理和高成本等挑战,类器官和器官芯片技术在妇产科领域的应用前景广阔,未来有望在临床诊断、药物研发和个性化医疗中发挥更大的作用。Significant progress has been made in the application of organoid and organ microarray technology in the field of obstetrics and gynecology. Organoids simulate the structure and function of human organs through three-dimensional culture technology, providing a new experimental model for the study of endometriosis, ovarian cancer and other gynecological diseases, revealing the molecular mechanism of the disease, and providing an important tool for drug screening and personalized treatment. Endometrial organoids can reproduce the menstrual cycle and embryo implantation process, providing a new perspective for the study of infertility and early pregnancy failure;ovarian organoids play an important role in the study of ovarian dysfunction and ovarian cancer. Organ chip technology provides a more accurate experimental platform by simulating the microenvironment of the uterus and placenta through a microfluidic system. Uterine microarrays have shown great potential in the study of menstrual cycle regulation, embryo implantation and uterine diseases;placental microarrays provide new methods for the study of pregnancy-related diseases and drug screening. Despite the challenges of technical standardization, ethics and high cost, organoids and organ chip technology have broad application prospects in the field of obstetrics and gynecology and are expected to play a greater role in clinical diagnosis, drug research and development and personalized medicine in the future.
文摘液体活检技术在妇科恶性肿瘤中的应用研究取得了显著进展,为临床诊断和治疗带来了新的希望。作为一种无创性检测方法,液体活检通过分析血液中的循环肿瘤细胞(CTCs)、循环肿瘤DNA (ctDNA)及外泌体等生物标志物,实现了对肿瘤的早期诊断、治疗监测和预后评估。其非侵入性和动态监测能力使其在克服传统组织活检局限性方面展现出独特优势。液体活检不仅能够为妇科恶性肿瘤的早期诊断做出贡献,还能在治疗过程中实时追踪肿瘤变化,指导个体化治疗策略的制定。然而,液体活检技术在临床应用中仍面临灵敏度、特异性、标准化等挑战。未来,随着技术的不断完善和研究的深入,液体活检有望在妇科恶性肿瘤的管理中发挥更为重要的作用,为患者提供更为精准和个性化的医疗服务。The application of liquid biopsy technique in gynecological malignant tumor has made remarkable progress, which brings new hope for clinical diagnosis and treatment. As a noninvasive test, liquid biopsy achieves early diagnosis, treatment monitoring, and prognostic evaluation of tumors by analyzing biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes in the blood. Its non-invasive and dynamic monitoring capabilities give it unique advantages in overcoming the limitations of traditional tissue biopsy. Liquid biopsy can not only contribute to the early diagnosis of gynecological malignancies, but also track tumor changes in real time during treatment and guide the development of individualized treatment strategies. However, liquid biopsy techniques still face challenges such as sensitivity, specificity, and standardization in clinical applications. In the future, with the continuous improvement of technology and the deepening of research, liquid biopsy is expected to play a more important role in the management of gynecological malignancies and provide more accurate and personalized medical services for patients.
